Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

  • Robert J. Moots,
  • Ricardo M. Xavier,
  • Chi Chiu Mok,
  • Mahboob U. Rahman,
  • Wen-Chan Tsai,
  • Mustafa H. Al-Maini,
  • Karel Pavelka,
  • Ehab Mahgoub,
  • Sameer Kotak,
  • Joan Korth-Bradley,
  • Ron Pedersen,
  • Linda Mele,
  • Qi Shen,
  • Bonnie Vlahos

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

  • Robert J. Moots, 
  • Ricardo M. Xavier, 
  • Chi Chiu Mok, 
  • Mahboob U. Rahman, 
  • Wen-Chan Tsai, 
  • Mustafa H. Al-Maini, 
  • Karel Pavelka, 
  • Ehab Mahgoub, 
  • Sameer Kotak, 
  • Joan Korth-Bradley
PLOS
x

The images for Figs 4, 5, and 6 are incorrectly switched. The image that appears as Fig 4 should be Fig 5, the image that appears as Fig 5 should be Fig 6, and the image that appears as Fig 6 should be Fig 4. The figure captions appear in the correct order.

Reference

  1. 1. Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai W-C, Al-Maini MH, et al. (2017) The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE 12(4): e0175207. pmid:28448562